简介 联系方式 药物互相作用: 390 212
根据名称进行药物检索

Aleve 与 Rasuvo

Aleve 与 Rasuvo互相作用以及同时服用的可能性。

检测结果:
Aleve <> Rasuvo
现实性: 12.08.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中,已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果,或起到良好效果。具体联合用药问题,需遵从医嘱。

用户:

生可能增加的血液水平和副作用的甲氨蝶呤。 你可能会更有可能遇到这种相互作用,如果你有肾病或正在接受高剂量的甲氨蝶呤。 风险可能更少,如果您使用的甲氨蝶呤每周一次来治疗某些形式的关节炎。 你可能需要的剂量调整或更频繁的监测通过你的医生到安全地使用这两种药物。 请立即联系医生如果你们出现症状的严重的潜在副作用的甲氨蝶呤如口腔炎或溃疡;呕吐;腹泻;疹;损失的食欲;关节疼痛或肿胀;黄色的皮肤和眼睛的黑暗尿;呼吸急促;干咳嗽;苍白;头晕或晕倒;不同寻常的瘀伤或漏;扣押;感染;以及类似流感的症状(热、冷、身体疼痛、喉咙疼痛、肌肉软弱). 重要的是要告诉你的医生关于所有其他药物的使用,包括维生素和草药。 不停止使用任何药物,没有第一个说你的医生。

医界专家:

密切监测:共同给予与非甾体抗炎药(非甾体抗炎药)的可能增加等离子浓度和毒性的甲氨蝶呤。 拟议的机制是非甾体抑制肾消除甲氨蝶呤及其代谢物,7-hydroxymethotrexate,尽管数据的药物动力学研究不一致和相互矛盾的。 位移的甲氨蝶呤结合血清白蛋白通过某些非甾体抗炎药也可以发挥辅助作用。 出乎意料的严重和有时是致命的抑制骨髓、再生障碍性贫血、胃肠毒性和肾毒性已报告期间,伴随政府的甲氨蝶呤与非甾体抗炎药. 风险最大的是在患者接受高剂量的甲氨蝶呤和肾损伤。 在临床研究中,甲氨蝶呤在剂量的7.5至15毫克/周已经用没有明显的问题,在患有风湿性关节炎的人,也收到恒定的药方案的非甾体抗炎药. 但是,已经有偶尔报告的口腔炎、肺炎、骨髓性毒性和致死在病人接受低剂量的周甲氨蝶呤有每日非甾体抗炎药.

管理:非甾体抗炎药一般不应给予之前或同时具有高剂量的甲氨蝶呤,例如用于治疗骨肉瘤。 应谨慎行事时,非甾体抗炎药施用伴随较低剂量的甲氨蝶呤。 密切监测为的迹象和症状的骨髓抑制肾毒性和肝毒性,建议在治疗。 患者应该建议联系他们的医生如果他们发展出口腔炎、恶心、呕吐、腹泻、皮疹,食欲减退、黄疸病、尿、干咳嗽呼吸急促,和/或迹象和症状的骨髓抑制,例如脸色苍白、头晕、疲劳、昏睡、昏厥,容易出血或血,热、冷、喉咙疼痛、身体疼痛和其他流感的症状。 病人也应该建议,以避免任何其他场非甾体产品。

来源
  • Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC "Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis." Br J Clin Pharmacol 37 (1994): 453-6
  • Schwartz JI, Agrawal NG, Wong PH, et al. "Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients." J Clin Pharmacol 41 (2001): 1120-30
  • Kraus A, Alarcon-Segovia D "Low dose MTX and NSAID induced "mild" renal insufficiency and severe neutropenia." J Rheumatol 18 (1991): 1274
  • Vakily M, Amer F, Kukulka MJ, Andhivarothai N "Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis." J Clin Pharmacol 45 (2005): 1179-86
  • Singh RR, Malaviya AN, Pandey JN, Guleria JS "Fatal interaction between methotrexate and naproxen." Lancet 1 (1986): 1390
  • Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC "The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis." Eur J Clin Pharmacol 42 (1992): 121-5
  • Brouwers JRBJ, Desmet PAGM "Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs." Clin Pharmacokinet 27 (1994): 462-85
  • Combe B, Edno L, Lafforgue P, Bologna C, Bernard JC, Acquaviva P, Sany J "Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients." Br J Rheumatol 34 (1995): 421-8
  • Baker H "Intermittent high dose oral methotrexate therapy in psoriasis." Br J Dermatol 82 (1970): 65-9
  • Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40
  • Ellison NM, Servi RJ "Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration." Cancer Treat Rep 69 (1985): 342-3
  • Franck H, Rau R, Herborn G "Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate." Clin Rheumatol 15 (1996): 163-7
  • Mayall B, Poggi G, Parkin JD "Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal." Med J Aust 155 (1991): 480-4
  • Anaya JM, Fabre D, Bressolle F, Bologna C, Alric R, Cocciglio M, Dropsy R, Sany J "Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis." J Rheumatol 21 (1994): 203-8
  • Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE "Aspirin alters methotrexate disposition in rheumatoid arthritis patients." Arthritis Rheum 34 (1991): 1514-20
  • Wallace CA, Smith AL, Sherry DD "Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis." J Rheumatol 20 (1993): 1764-8
  • Hartmann SN, Rordorf CM, Milosavljev S, et al. "Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients." Ann Pharmacother 38 (2004): 1582-7
  • Thyss A, Milano G, Kubar J, Namer M, Schneider M "Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen." Lancet 1 (1986): 256-8
  • Matheson AJ, Figgitt DP "Rofecoxib - A review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis." Drugs 61 (2001): 833-65
  • "Product Information. Arthrotec (diclofenac-misoprostol)." Searle, Skokie, IL.
  • Bloom EJ, Ignoffo RJ, Reis CA, Cadman E "Delayed clearance (CL) of methotrexate (MTX) associated with antibiotics and antiinflammatory agents." Clin Res 34 (1986): a560
  • Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM "Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis." J Rheumatol 17 (1990): 1469-73
  • Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H "Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis." J Rheumatol 17 (1990): 1008-10
  • Maiche AG "Acute renal failure due to concomitant action of methotrexate and indomethacin." Lancet 1 (1986): 1390
  • Frenia ML, Long KS "Methotrexate and nonsteroidal antiinflammatory drug interactions." Ann Pharmacother 26 (1992): 234-7
  • Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS "Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis." J Rheumatol 26 (1999): 2539-43
  • EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
  • Ng HW, Macfarlane AW, Graham RM, Verbov JL "Near fatal drug interactions with methotrexate given for psoriasis." Br Med J (Clin Res Ed) 295 (1987): 752-3
  • Stewart CF, Fleming RA, Arkin CR, Evans WE "Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis." Clin Pharmacol Ther 47 (1990): 540-6
Aleve

非专利名称: naproxen

品牌: Aleve, EC-Naprosyn, Flanax Pain Reliever, Midol Extended Relief, Naprelan 375, Naprosyn, Anaprox-DS, Naprelan 500, Flanax, Naprelan, Anaprox, Naproxen Sodium, Aleve Caplet, Aleve Gelcap, Aleve Easy Open Arthritis

同义词:

Rasuvo

非专利名称: methotrexate

品牌: Methotrexate Sodium, Preservative Free, Otrexup, Rasuvo, Rheumatrex Dose Pack, Trexall, Xatmep

同义词: Rasuvo (injection), Rasuvo Injection

在药物相容性与互相作用的检测过程中使用下列的信息来源:Drugs.com, Rxlist.com, Webmd.com, Medscape.com。

与食物,生活方式相互作用
与疾病相互作用